The DEXA SOLO-L ALIF device allows doctors to match the implant to patients' bone density and quality.
The US Food and Drug Administration (FDA) has granted 510K clearance for Aurora Spine’s DEXA SOLO-L anterior lumbar interbody fusion device (ALIF).
Please enter a work/business email address
By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Based on the company’s DEXA Technology Platform, the 3D printed standalone device has been designed for anterior and lateral lumbar interbody fusion (ALIF & LLIF) procedures.
The DEXA SOLO-L spinal fusion system was developed as a bone density matched implant and is claimed to be the first device of its kind for the lumbar spine.
It is also the first colour-coded, bone mimicking ALIF standalone device on the market, enabling doctors to match the implant to a patient’s bone density and quality.
Aurora Spine president and CEO Trent Northcutt said: “We are thrilled to receive this new approval for our DEXA SOLO-L device, the world’s first patented and FDA-cleared, colour-coded ALIF standalone device.
“This clearance is an important step to gain new surgeon customers and new sales distribution opportunities nationwide to drive more revenue.”
The company claims that its DEXA implants are the world’s first implants that match patient bone density and quality to provide a personalised implant.
The launch of the DEXA-L product line follows the recent release of the DEXA-C cervical implant product line.
Aurora Spine chief technology officer Laszlo Garamszegi said: “The DEXA SOLO-L approval demonstrates our unwavering commitment to game-changing innovation around our entire bone mimicking DEXA Technology Platform.
“We will continue developing proprietary products to strengthen our product offerings, and build off our patent portfolio, especially our patented DEXA Technology Platform.”
Precision Micro, Small and Lead Frame / Insert Injection-Molded Plastic Components
Blood and Urine Collection and Safety Systems
GlobalData exists to help businesses decode the future to profit from faster, more informed decisions.
Please enter a work/business email address
By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you for subscribing to Medical Device Network